Skip to main content

Ceftriaxone (ceftriaxone sodium and dextrose injection ) Sodium is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to Ceftriaxone (ceftriaxone sodium and dextrose injection ) Sodium therapy or of uncertain etiology, were observed:

LOCAL REACTIONS — Phlebitis was reported in < 1% after IV administration.

HYPERSENSITIVITY — rash (1.7%). Less frequently reported ( < 1 %) were pruritus, fever or chills.

HEMATOLOGIC — eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%). Less frequently reported ( < 1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time.

GASTROINTESTINAL — diarrhea (2.7%). Less frequently reported ( < 1%) were nausea or vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).

HEPATIC — elevations of SGOT (3.1%) or SGPT (3.3%). Less frequently reported ( < 1%) were elevations of alkaline phosphatase and bilirubin.

RENAL — elevations of the BUN (1.2%). Less frequently reported ( < 1 %) were elevations of creatinine and the presence of casts in the urine.

CENTRAL NERVOUS SVSTEM — headache or dizziness were reported occasionally ( < 1%).

GENITOURINARY — moniliasis or vaginitis were reported occasionally ( < 1 %).

MISCELLANEOUS — diaphoresis and flushing were reported occasionally ( < 1%).

Other rarely observed adverse reactions ( < 0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness.